bjh12394-sup-0001-TableS1-S4_FigS1-S7.docWord document2264K

Table SI. Demographic, serological and molecular features of the patients included in the miRNA expression analysis compared with those who entered into the overall trial.

Table SII. The specific deregulation of miRNAs in (A) 4p16, (B) MAF and (C) 11q13 subtypes compared to other subtypes (SAM, FDR < 0·05 based on 1000 permutations).

Table SIII. miRNAs associated with PFS (unadjusted < 0·05).

Table SIV. Putative targets of miR-886-5p identified using the selection criteria described in methods (ranked by P values for correlation between miRNA and mRNA expression).

Fig S1. Coexpression between individual miRNAs within the same cluster or family.

Fig S2. Density plots showing expression pattern of miR-17, miR-18a and miR-886-5p across 163 samples and the thresholds for high and low expression.

Fig S3. Kaplan-Meier estimated curves of the groups defined by high/low expression levels of (A) miR-886-5p and (B) miR-17, which is consistent across both treatment pathways.

Fig S4. The three risk groups based on 2-miRNA-classifier remain significant on myeloma-specific survival, excluding the possibility that their association with OS is due to non-myeloma-related mortalities.

Fig S5. Kaplan-Meier estimated curves in Myeloma IX GEP set (= 261) of the groups defined by the expression levels of the candidate target for miR-886-5p, NR3C1. Lower expression of NR3C1 (1st quartile) is associated with shorter OS.

Fig S6. Boxplot distribution showing the associations between expression levels of miR-17/miR-886-5p and cytogenetic subgroups (Wilcoxon test).

Fig S7. The correlation analyses of miRNA expression and their copy numbers show that the expression levels of miR-886-5p and miR-17 are not copy number sensitive.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.